logo
logo

Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing

Dec 08, 2020•over 4 years ago

Amount Raised

$81 Million

Cambridge

Description

 Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing to address the underlying drivers of disease, launched today with $81 million in financing. The funds will support development of the company's REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics. The Series A round was led by Foresite Capital with participation from seed investors Atlas Venture and The Column Group. Additional investors joining the financing included Arch Venture and Alexandria Venture Investments.

Company Information

Company

Remix Therapeutics

Location

Cambridge, Maryland, United States

About

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix's innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com. SOURCE Remix Therapeutics

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech